Cost-effectiveness of insulin degludec versus insulin glargine U100 in adults with type 1 and type 2 diabetes mellitus in Bulgaria

Table 2 Calculation of hypoglycaemia event rates

	Non-severe hypoglycaemia		Severe hypoglycaemia
	Daytime	Nocturnal	Severe hypoglycaemia
T1DM
Total events/patient/year for glargine U100^a	30.42	8.52	3.20
Degludec/glargine U100 hypoglycaemic event rate ratio^b	Not Significant	0.83*	Not significant
Calculated degludec hypoglycaemic event rate	30.42	7.07	3.20
T2DM_BOT
Total events/patient/year for glargine U100^a	23.12	13.38	0.10
Degludec/glargine U100 hypoglycaemic event rate ratio^b	Not significant	0.64*	0.14*
Calculated degludec hypoglycaemic event rate	23.11	8.57	0.01
T2DM_B/B
Total events/patient/year for glargine U100^a	30.42	8.52	0.70
Degludec/glargine U100 hypoglycaemic event rate ratio^b	0.83*	0.75*	Not significant
Calculated degludec hypoglycaemic event rate	25.25	6.39	0.70

Abbreviations: B/B Basal-bolus, BOT Basal oral therapy, T1DM Type 1 diabetes mellitus, T2DM Type 2 diabetes mellitus.
* p < 0.05; NS Non-significant; in the case of non-significant results, a relative rate of one was used in the calculation
^a Taken from Brod et al. [37] and UK Hypoglycaemia Study Group [36]
^b Taken from Vora et al. [27]

ISSN: 1472-6823